Stryker to Buy ZuriMED, Adding FiberLocker to Shoulder Portfolio

By Elena Rossi

Stryker announced on August 31, 2026 that it has signed a definitive agreement to acquire ZuriMED, a privately held company that develops the FiberLocker System, a commercialized technology for rotator cuff augmentation.

According to the announcement from the Portage, Michigan-based medical technology company, the FiberLocker System provides a novel approach for rotator cuff augmentation designed to deliver increased biomechanical strength and to address a key clinical failure mode in rotator cuff repair. Stryker stated that the acquisition will strengthen its shoulder portfolio and enhance its ability to support shoulder specialists across both sports medicine and arthroplasty. The company described rotator cuff augmentation as one of the fastest-growing areas in sports medicine, citing a Mordor Intelligence market report on rotator cuff treatment.

“ZuriMED has developed a differentiated technology that addresses an important clinical need within shoulder care,” said Andy Pierce, Group President, MedSurg and Neurotechnology at Stryker. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio.”

Pierce added that the acquisition reflects the company’s continued commitment to advancing innovation and improving patient outcomes. Financial terms of the transaction were not disclosed in the announcement. The transaction is subject to customary closing conditions, and Stryker and ZuriMED will continue to operate as separate entities and proceed with business as usual until the transaction closes.

The FiberLocker System

ZuriMED describes the FiberLocker System as a mechanical augmentation technology for rotator cuff repair. According to the company’s product documentation, the patented FiberLock technology enables the formation of a strong, interwoven network between a patch and tendon tissue. During implantation, the instrument’s reciprocating needle pushes implant fibers into the underlying soft tissue, securing the company’s SpeedPatch implant across the entire patch-tendon interface and producing what the company characterizes as immediate mechanical augmentation.

The system consists of the FiberLocker Instrument and the SpeedPatch. ZuriMED states that implantation is completed in 90 seconds, and that ex vivo testing has shown significantly increased biomechanical strength of augmented rotator cuff repairs at time zero. The company also reports that animal studies demonstrated cell infiltration into the porous scaffold.

On its website, ZuriMED describes the clinical problem the device targets. After a tear, the rotator cuff tendon is typically repaired using sutures and bone anchors, but the tendon often cannot withstand suture fixation because of its compromised structural integrity, leading to failure at the suture-tendon interface, a phenomenon commonly referred to as cheesewiring. The company states that postoperative retear rates have been reported to range from 24% to 94%, and cites published literature indicating that suture cut-through is the primary cause of failure, accounting for 86% of cases in one cited study.

Regulatory Status and Clinical Studies

ZuriMED announced on February 3, 2025 that the FiberLocker System had received FDA 510(k) clearance, and said the system would enter the U.S. market in the first quarter of 2025. The company states the system is currently commercially available only in the United States.

Two prospective clinical studies investigating the performance and safety of the FiberLocker System are ongoing, according to the company. A first-in-human study conducted at Balgrist University Hospital marks the first clinical use of the system in Switzerland and is investigating its safety. A separate multicenter study is being conducted across multiple centers in the United States, with healing based on MRI as the primary outcome.

ZuriMED, formally ZuriMED Technologies AG, is a Zurich-based company that specializes in orthopedic biomechanics. In August 2023, the company announced the closure of a Series A financing round totaling 14.5 million Swiss francs, which it said would support its path to market entry for its Surgical-Fiberlock technology.

Stryker, listed on the New York Stock Exchange under the symbol SYK, offers products and services in MedSurg, Neurotechnology and Orthopaedics and states that, alongside its customers, it impacts more than 150 million patients annually.